



SIMPLE *cis*-EPOXIDE-BASED INHIBITORS OF HIV-1 PROTEASE

Andrew D. Abell,^{*,a} Deborah A. Hoult,^a Douglas A. Bergman,^b and David P. Fairlie^b


^aDepartment of Chemistry, University of Canterbury, Christchurch, New Zealand

^bCentre for Drug Design and Development, University of Queensland, Brisbane, Qld. 4072 Australia

Abstract: The 4-nitrophenoxy-based epoxide **6a**, conveniently synthesized using Sharpless epoxidation chemistry, has been shown to be an irreversible inhibitor of HIV-1 protease (K_{inact} 1.8 μM , pH 6.5, $I = 0.1 \text{ M}$). Related analogues, differing in the mode of attachment to the epoxide core, have also been prepared and assayed against HIV-1 protease. © 1997 Elsevier Science Ltd.

The use of inhibitors of HIV-1 protease is now established as a viable treatment for patients with acquired immunodeficiency syndrome (AIDS).¹ Many peptidomimetic transition state analogue inhibitors of this enzyme have been identified with nanomolar and subnanomolar K_i values and a number of these have now been approved for the treatment of AIDS.¹ However, the need still exists to identify new inhibitors of HIV protease to combat problems associated with the appearance of drug resistant strains of HIV² and the expense and difficulties associated with the available treatments.³ To this end, we have embarked on a programme to identify novel and simple leads for the development of potent inhibitors of HIV-1 protease.

To date, a few epoxide-based inhibitors of HIV-1 protease have been reported. 1,2-Epoxy-3-(4-nitrophenoxy)propane (EPNP; **1**) is a nonspecific, irreversible inhibitor of HIV-1 protease (K_{inact} 11 mM).⁴ The nitrophenoxy group of EPNP is thought to reside in the S1 pocket of the enzyme active site. The tripeptidomimetic epoxide **2** was subsequently developed, based on the known specificity of HIV-1 protease, to span the S3-S1' substrate-binding sites with the epoxy group binding in place of the scissile P1-P1' peptide bond ($K_{\text{inact}} = 20 \mu\text{M}$).⁵ *Cis* epoxide-based inhibitors of the type **3** have also been recently reported as time-dependent, irreversible inhibitors of HIV-1 protease.⁶ An increase in the potency of these inhibitors was obtained by extending the peptide sequence to span the S2-S3' binding domains. C_2 -Symmetric epoxides of the type **4** are reversible inhibitors of HIV-1 protease ($K_i = 75 \text{ nM}$)⁷ while the non-peptidic epoxide **5** is an irreversible, active-site directed inhibitor of HIV-1 protease ($K_{\text{inact}} = 65 \mu\text{M}$).⁸ Compound **5** was designed using the known non-peptidic inhibitor, haloperidol, as the lead structure.




In this paper, we wish to report our initial studies on the synthesis and inhibition of HIV-1 protease by two series of simple *cis*-epoxides. The two series differ in the mode of amino acid attachment to an epoxide core structure, either **10** or **11**. Compounds **6** have an ester linkage to **10**, while **12** and **13** have an amide linkage to **11**. These compounds were designed to combine the nitrophenoxy group of EPNP (**1**) with a *cis*-epoxide, which is common to all the before mentioned literature inhibitors. We also required the compounds to be readily prepared, as single isomers, from simple starting materials.

The synthesis of compounds **6**, **12**, and **13** is given in the Scheme. A Horner–Wittig olefination of separate samples of the aldehydes **7a** and **7b** gave the *cis* α,β -unsaturated esters **8** (traces of the *trans* isomers were readily separable by chromatography). A diisobutylaluminium hydride (DIBAL) reduction of **8** gave the allylic alcohols **9**, which were converted into the key epoxides **10** under Sharpless conditions.⁹ Condensation of **10a** with either Cbz-Val or Cbz-Val-Val, under Mitsunobu conditions,¹⁰ then gave **6a** and **6b** (step v). Oxidation of **10a** and **10b** gave **11a** and **11b**, which underwent a BOP catalysed coupling with the methyl esters of either Val or Leu, to give compounds **12** and **13** (step vi).

The Table shows preliminary data for the inhibition of HIV-1 protease by compounds **6**, **12**, and **13** (a K_{inact} value was determined for the most potent derivative, **6a**). The first point about the data is that compounds of type **6** are more potent than the amide-linked analogues, **12** and **13**. Compound **6a** inhibited HIV-1 protease in a time-dependent manner. This inactivation was irreversible since enzyme activity was not recovered by exhaustive dialysis. A double reciprocal plot of inactivation rates (k_{obs}) versus inhibitor concentration⁴ yielded values of 1.8 μM for K_{inact} (the concentration of inhibitor giving the half-maximum inactivation rate), 0.26 min^{-1} for V_{inact} (the maximal inactivation rate) and $1.4 \times 10^5 \text{ M}^{-1} \text{ min}^{-1}$ for $V_{\text{inact}}/K_{\text{inact}}$ (the bimolecular rate constant), which makes it significantly more potent than model epoxide EPNP. The addition of a reversible competitive inhibitor (DMP323, 100 nM)¹² protected the enzyme from inactivation by 10 mM of compound **6a**,

causing a 7.5-fold reduction in the apparent bimolecular rate constant. This result is consistent with compound **6a** reacting with an active-site residue.



(i) $[\text{PhO})_2\text{POCCO}_2\text{Me}]\text{Li}^+$, $-78\text{ }^\circ\text{C}$; (ii) DIBAL, $-78\text{ }^\circ\text{C}$; (iii) $\text{Ti}(\text{O}i\text{Pr})_4$, L-DIPT, TBHP; (iv) RuCl_3 , H_5IO_6 ; (v) RCO_2H , Ph_3P , DEAD; (vi) $\text{Cl}\cdot\text{H}_3\text{NCHRCO}_2\text{Me}$, BOP.

The incorporation of a second Val, as in **6b**, resulted in a significant decrease in potency towards HIV-1 protease. A nitrophenoxymethyl group, as in **6** and **13**, would appear to provide slightly more potent compounds than a phenylethyl group, as in **12**. Ongoing work is directed towards optimising the substituents and configuration of this new and readily prepared series of HIV-1 protease inhibitors.

Table. Inhibition of HIV-1 protease.¹¹

Compound	R^2	% Inhibition ^a
6a	Val-NHCbz	88% ^b ($K_{\text{inact}} = 1.8\text{ }\mu\text{M}$)
6b	Val-Val-NHCbz	25% ^b
12	Leu-OMe	19%
13a	Val-OMe	22%
13b	Leu-OMe	30%

^aAfter 1 min, pH 6.5, I 0.1 M, 37 $^\circ\text{C}$, 50 μM [S], 200 μM [I].

^bAt 20 μM [I].

References and Notes

- Kempf, D. J.; Sham, H. L. *Current Pharmaceutical Design* **1996**, 2, 225. March, D. R.; Fairlie, D. P. In *HIV-1 Protease and its Inhibitors*; Wise, R., Ed.; R. G. Landes: Austin, 1996; pp 1–88.
- Erickson, J. W. *Nature Structural Biology* **1995**, 2, 523.
- Day, M. *New Scientist* **1997**, 4.

4. Meek, T. D.; Dayton, B. D.; Metcalf, B. W.; Dreyer, G. B.; Strickler, J. E.; Gorniak, J. G.; Rosenberg, M.; Moore, M. L.; Magaard, V. W.; Debouck, C. *Proc. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 1841.
5. Grant, S. K.; Moore, M. L.; Fakhoury, S. A.; Tomaszek, T. A.; Meek, T. D. *Bioorg. Med. Chem. Lett.* **1992**, *2*, 1441.
6. Lee, C. S.; Choy, N.; Park, C.; Choi, H.; Son, Y. C.; Kim, S.; Ok, J. H.; Yoon, H.; Kim, S. C. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 589.
7. Park, C.; Koh, J. S.; Son, Y. C.; Choi, H.; Lee, C. S.; Choy, N.; Moon, K. Y.; Jung, W. H.; Kim, S. C.; Yoon, H. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 1843.
8. Yu, Z.; Caldera, P.; De Voss, J. J.; Jones, P. R.; Burlingame, A. L.; Kuntz, I. D.; Craik, C. S.; Ortiz de Montellano, P. R. *J. Am. Chem. Soc.* **1996**, *118*, 5846.
9. Finn, M. G.; Sharpless, K. B. In *Asymmetric Synthesis*; Morrison, J. D., Ed.; Academic: New York, 1985; Vol. 5, Chapter 8, p 247.
10. Mitsunobu, O. *Synthesis* **1981**, 1.
11. Bergman, D. A.; Alewood, D.; Alewood, P. F.; Andrews, J. L.; Brinkworth, R. I.; Englebrechtsen, D. R.; Kent, S. B. H. *Lett. Pept. Sci.* **1995**, *2*, 99.
12. Lam, P. Y. S.; Jadhav, P. K.; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. *Science* **1994**, *263*, 380.

(Received in USA 4 June 1997; accepted 6 October 1997)